parthenolide has been researched along with Hepatocellular Carcinoma in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Z; Liu, X; Shen, Y; Wang, X | 1 |
| Chen, T; Chen, Y; Ding, Y; Ge, W; Li, S; Liu, Z; Wang, M; Zhang, Q; Zhang, X | 1 |
| Jiang, S; Liang, P; Lv, H; Wu, H; Zhang, Z | 1 |
| Li, Y; Liu, D; Liu, M; Liu, Y; Ran, L | 1 |
| Bao, YL; Chen, ZL; Huang, YX; Li, YX; Sun, J; Sun, Y; Wang, X; Wu, Y; Yu, CL; Zhang, C; Zheng, LH | 1 |
| Angileri, L; Carlisi, D; D'Anneo, A; Emanuele, S; Lauricella, M; Santulli, A; Tesoriere, G; Vento, R | 1 |
| Choi, YK; Kim, DG; Liu, MJ; Won, YS; You, KR | 1 |
| Kim, DG; Lee, SY; Song, CH; Wen, J; You, KR | 1 |
| Kim, DG; Kim, IH; Kim, JH; Liu, L; Park, JH; You, KR | 1 |
| Chen, C; Jain, MR; Jeong, WS; Keum, YS; Kim, JH; Kong, AN; Li, W; Shen, G | 1 |
| Gage, EA; Klein, PJ; Ralstin, MC; Schmidt, CM; Wiebke, EA; Yip-Schneider, MT | 1 |
| Bugno, M; Kasza, A; Kordula, T; Sobota, R; Szwed, M | 1 |
12 other study(ies) available for parthenolide and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Parthenolide targets NF-κB (P50) to inhibit HIF-1α-mediated metabolic reprogramming of HCC.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Hypoxia-Inducible Factor 1, alpha Subunit; Lactates; Liver Neoplasms; Mice; NF-kappa B; Sesquiterpenes | 2022 |
Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Nucleus; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Liver Neoplasms; Molecular Structure; Sesquiterpenes; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Preparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Compounding; Drug Liberation; Drug Stability; Drug Synergism; Female; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Sesquiterpenes; Solubility; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Reversing resistance of multidrug-resistant hepatic carcinoma cells with parthenolide.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver Neoplasms; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Sesquiterpenes; Tumor Suppressor Protein p53; Wnt1 Protein | 2013 |
Parthenolide-induced apoptosis, autophagy and suppression of proliferation in HepG2 cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Fluorescent Antibody Technique; Hep G2 Cells; Humans; Liver Neoplasms; Sesquiterpenes | 2014 |
Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation.
Topics: Apoptosis; Carcinoma, Hepatocellular; Caspases; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Activation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Janus Kinases; Liver Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-mdm2; Receptors, Death Domain; Sesquiterpenes; STAT3 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53 | 2011 |
GADD153-mediated anticancer effects of N-(4-hydroxyphenyl)retinamide on human hepatoma cells.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Proteins; Cell Cycle; DNA Fragmentation; Fenretinide; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation; Genes, Reporter; Humans; Neoplasms; NF-kappa B; Sesquiterpenes; Transcription Factor CHOP; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Hepatocellular; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Cycle; Cell Division; Cytochrome c Group; Flow Cytometry; Glutathione; Humans; Membrane Potentials; Oxidative Stress; Sesquiterpenes; Transcription Factor CHOP; Transcription Factors; Tumor Cells, Cultured | 2002 |
Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells.
Topics: Amino Acid Sequence; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Drug Synergism; Fenretinide; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Molecular Sequence Data; Muscle Proteins; NF-kappa B; Nuclear Proteins; Polymerase Chain Reaction; Repressor Proteins; RNA, Messenger; Sesquiterpenes; Up-Regulation | 2005 |
Differential expression and stability of endogenous nuclear factor E2-related factor 2 (Nrf2) by natural chemopreventive compounds in HepG2 human hepatoma cells.
Topics: Anticarcinogenic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA-Binding Proteins; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Isothiocyanates; Kelch-Like ECH-Associated Protein 1; Liver Neoplasms; Membrane Proteins; NF-E2-Related Factor 2; Proteins; Sesquiterpenes; Sulfoxides; Thiocyanates; Trans-Activators; Transcriptional Activation | 2005 |
Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cyclooxygenase Inhibitors; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Humans; I-kappa B Proteins; Interphase; NF-kappa B; Nitrobenzenes; Sesquiterpenes; Sulfonamides; Transcription, Genetic | 2006 |
Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family.
Topics: Acute-Phase Proteins; alpha 1-Antichymotrypsin; Carcinoma, Hepatocellular; Cytokines; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Interleukin-1; Interleukin-6; Liver Neoplasms; NF-kappa B; Oncostatin M; Peptides; Recombinant Fusion Proteins; Sesquiterpenes; Signal Transduction; STAT3 Transcription Factor; Trans-Activators; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 2000 |